Combined clinical and laboratory investigations of multiple endocrine neoplasia type 1 (MEN1) have resulted in an increased understanding of this disorder which may be inherited as an autosomal dominant condition. Defining the features of each disease manifestation in MEN1 has improved patient management and treatment, and has also facilitated a screening protocol to be instituted. The application of the techniques of molecular biology has enabled the identification of the gene causing MEN1 and the detection of mutations in patients. The function of the protein encoded by the MEN1 gene has been shown to be in the regulation of JunD-mediated transcription but much still remains to be elucidated. However, these recent advances provide for the identification of mutant MEN1 gene carriers who are at a high risk of developing this disorder and thus require regular and biochemical Endocrine-Related Cancer (1999) 6 449-473 screening to detect the development of endocrine tumours.
Introduction
Multiple endocrine neoplasia (Thakker & Ponder 1988 , Thakker 1995 , Marx 1998 ) is characterised by the occurrence of tumours involving two or more endocrine glands within a single patient. The disorder has previously been referred to as multiple endocrine adenopathy (MEA) or the pluriglandular syndrome. However, glandular hyperplasia and malignancy may also occur in some patients and the term multiple endocrine neoplasia (MEN) is now preferred. There are two major forms of multiple endocrine neoplasia referred to as type 1 and type 2 and each form is characterised by the development of tumours within specific endocrine glands (Table 1) . Thus, the combined occurrence of tumours of the parathyroid glands, the pancreatic islet cells and the anterior pituitary is characteristic of multiple endocrine neoplasia type 1 (MEN1), which is also referred to as Wermer's syndrome (Wermer 1954) . In addition to these tumours, adrenal cortical, carcinoid, facial angiofibromas, collagenomas and lipomatous tumours have also been described in patients with MEN1 (Trump et al. 1996 , Marx 1998 . However, in multiple endocrine neoplasia type 2 (MEN2), which is also called Sipple's syndrome (Sipple 1961) , medullary thyroid carcinoma (MTC) occurs in association with phaeochromocytoma, and three clinical variants, referred to as MEN2a, MEN2b and MTC-only, are recognised (Thakker & Ponder 1988 , Thakker 1998 . In MEN2a, which is the most common variant, the development of MTC is associated with phaeochromo-cytoma and parathyroid tumours. However, in MEN2b parathyroid involvement is absent and the occurrence of MTC and phaeochromocytoma is found in association with a marfanoid habitus, mucosal neuromas, medullated corneal fibres and intestinal autonomic ganglion dysfunction leading to a megacolon. In the variant of MTC-only, medullary thyroid carcinoma appears to be the sole manifestation of the syndrome. Although MEN1 and MEN2 usually occur as distinct and separate syndromes as outlined above, some patients occasionally may develop tumours which are associated with both MEN1 and MEN2. For example, patients suffering from islet cell tumours of the pancreas and phaeochromocytomas or from acromegaly and phaeochromocytoma have been described and these patients may represent 'overlap' syndromes. All these forms of MEN may either be inherited as autosomal dominant syndromes, or they may occur sporadically i.e. without a family history. However, this distinction between sporadic and familial cases may sometimes be difficult as in some sporadic the family history may be absent because the parent with the disease may have died before developing symptoms. In this review, the main clinical features, molecular genetics, and recent progress in the study of MEN1 will be discussed
Clinical features of MEN1
The incidence of MEN1 has been estimated from randomly chosen post mortem studies to be 0.25%, and to be % amongst patients with primary hyperpara-thyroidism (Marx et al. 1982 , Thakker 1995 . The disorder affects all age groups, with a reported age range of 8-81 years, and >95% of patients have developed clinical manifestations of the disorder by the fifth decade (Thakker 1995 , Trump et al. 1996 , Bassett et al. 1998 . The clinical manifestations of MEN1 are related to the sites of tumours and to their products of secretion. In addition to the triad of parathyroid, pancreatic and pituitary tumours, which constitute the major components of MEN1, adrenal cortical, carcinoid, facial angiofibromas, collagenomas and lipomatous tumours have also been described (Trump et al. 1996 , Marx 1998 .
Parathyroid tumours
Primary hyperparathyroidism is the most common feature of MEN1 and occurs in more than 95% of all MEN1 patients (Benson et al. 1987 , Marx et al. 1986 ,Thakker 1995 , Trump et al. 1996 . Patients may present with asymptomatic hypercalcaemia, or nephrolithiasis, or osteitis fibrosa cystica or vague symptoms associated with hypercalcaemia, for example polyuria, polydipsia, constipation, malaise or occasionally with peptic ulcers. Biochemical investigations reveal hypercalcaemia usually in association with raised circulating parathyroid hormone (PTH) concentrations. No effective medical treatment for primary hyperparathyroidism is generally available and surgical removal of the abnormally overactive parathyroids is the definitive treatment. However, all four parathyroid glands are usually affected with multiple adenomas or hyperplasia, although this histological distinction may be difficult, and total parathyroidectomy has been proposed as the definitive treatment for primary hyperparathyroidism in MEN1, with the resultant lifelong hypocalcaemia being treated with oral calcitriol (1,25-dihydroxy vitamin D 3 ) (Rizzoli et al. 1985) . It is recommended that such total parathyroidectomy should be reserved for the symptomatic hypercalcaemic patient with MEN1, and that the asymptomatic hypercalcaemic MEN1 patient should not have parathyroid surgery but have regular assessments for the onset of symptoms and complications, when total parathyroidectomy should be undertaken.
Pancreatic tumours
The incidence of pancreatic islet cell tumours in MEN1 patients varies from 30 to 80% in different series (Thakker & Ponder 1988 , Thakker 1995 , Trump et al. 1996 . The majority of these tumours produce excessive amounts of hormone, for example gastrin, insulin, glucagon or vasoactive intestinal polypeptide (VIP), and are associated with distinct clinical syndromes.
Gastrinomas
These gastrin-secreting tumours represent over 50% of all pancreatic islet cell tumours in MEN1, and are the major cause of morbidity and mortality in MEN1 patients. This is due to the recurrent severe multiple peptic ulcers which may perforate. This association of recurrent peptic ulceration, marked gastric acid production and non β-islet cell tumours of the pancreas is referred to as the Zollinger-Ellison syndrome (Zollinger & Ellison 1955) . Additional prominent clinical features of this syndrome include diarrhoea and steatorrhoea. The diagnosis is established by demonstration of a raised fasting serum gastrin concentration in association with an increased basal gastric acid secretion (Wolfe & Jensen 1987) . Medical treatment of MEN1 patients with the Zollinger-Ellison syndrome is directed at reducing basal acid output to less than 10 mmol/l, and this may be achieved by the parietal cell H + -K + -ATPase inhibitor, omeprazole. The ideal treatment for a non-metastatic gastrinoma is surgical excision of the gastrinoma. However, in patients with MEN1 the gastrinomas are frequently multiple or extrapancreatic and surgery has not been successful (Delcore et al. 1989 , Sheppard et al. 1989 . The treatment of disseminated gastrinomas is difficult and hormonal therapy with octreotide, which is a human somatostatin analogue, chemotherapy with streptozotocin and 5-fluoroaracil, hepatic artery embolisation, and removal of all resectable tumour have all occasionally been successful (Thakker 1995) .
Insulinoma
These β-islet cell tumours secreting insulin represent onethird of all pancreatic tumours in MEN1 patients (Thakker 1995 , Trump et al. 1996 . Insulinomas also occur in association with gastrinomas in 10% of MEN1 patients, and the two tumours may arise at different times. Patients with an insulinoma present with hypoglycaemic symptoms which develop after a fast or exertion and improve after glucose intake. Biochemical investigations reveal raised plasma insulin concentrations in association with hypoglycaemia. Circulating concentrations of C-peptide and proinsulin, which are also raised, may be useful in establishing the diagnosis, as may an insulin suppression test. Medical treatment, which consists of frequent carbohydrate feeds and diazoxide, is not always successful and surgery is often required. Most insulinomas are multiple and small and preoperative localisation with computed tomography scanning, coeliac axis angiography and pre-perioperative percutaneous transhepatic portal venous sampling is difficult and success rates have varied. Surgical treatment, which ranges from enucleation of a single tumour to a distal pancreatectomy or partial pancreatectomy, has been curative in some patients. Chemotherapy, which consists of streptozotocin or octreotide, is used for metastatic disease.
Glucagonoma
These α-islet cell, glucagon-secreting pancreatic tumours, have been reported in a few MEN1 patients (Thakker 1995 , Trump et al. 1996 , Bassett et al. 1997 , Marx 1998 ).
The characteristic clinical manifestations of a skin rash (necrolytic migratory erythyema), weight loss, anaemia and stomatitis may be absent and the presence of the tumour is indicated only by glucose intolerance and hyperglucagonaemia. The tail of the pancreas is the most frequent site for glucagonomas and surgical removal of these is the treatment of choice. However, treatment may be difficult as 50% of patients have metastases at the time of diagnosis. Medical treatment of these with octreotide, or with streptozotocin has been successful in some patients.
VIPoma
Patients with VIPomas, which are vasoactive intestinal peptide (VIP)-secreting pancreatic tumours, develop watery diarrhoea, hypokalaemia and achlorhydria, referred to as the WDHA syndrome (Marx et al. 1967 ).
This clinical syndrome has also been referred to as the Verner-Morrison syndrome (Verner & Morrison 1958) or the VIPoma syndrome (Bloom et al. 1973) . VIPomas have been reported in only a few MEN1 patients and the diagnosis is established by documenting a markedly raised plasma VIP concentration (Thakker 1995) . Surgical management of VIPomas, which are mostly located in the tail of the pancreas, has been curative. However, in patients with unresectable tumour, treatment with streptozotocin, octreotide, corticosteroids, indomethacin, metoclopramide and lithium carbonate has proved beneficial.
PPoma
These tumours, which secrete pancreatic polypeptide (PP) are found in a large number of patients with MEN1 (Friesen et al. 1980 , Skogseid et al. 1987 , Thakker 1995 .
No pathological sequelae of excessive PP secretion are apparent and the clinical significance of PP is unknown, although the use of serum PP measurements has been suggested for the detection of pancreatic tumours in MEN1 patients.
Pituitary tumours
The incidence of pituitary tumours in MEN1 patients varies from 15 to 90% in different series (Thakker 1995 , Trump et al. 1996 . Approximately 60% of MEN1associated pituitary tumours secrete prolactin, 25% secrete growth hormone (GH), 3% secrete adenocorticotrophin (ACTH) and the remainder appear to be non-functioning. The clinical manifestations depend upon the size of the pituitary tumour and its product of secretion. Enlarging pituitary tumours may compress adjacent structures such as the optic chiasm or normal pituitary tissue and cause bitemporal hemianopia or hypopituitarism respectively. The tumour size and extension are radiologically assessed by computed tomography scanning and nuclear magnetic resonance imaging. Treatment of pituitary tumours in MEN1 patients is similar to that in non-MEN1 patients and consists of medical therapy or selective hypophysectomy by the transphenoidal approach if feasible, with radiotherapy being reserved for residual unresectable tumour.
Associated tumours
Patients with MEN1 may have tumours involving glands other than the parathyroids, pancreas and pituitary. Thus carcinoid, adrenal cortical, facial angiofibromas, collagenomas, thyroid and lipomatous tumours have been described in association with MEN1 (Thakker 1995 , Trump et al. 1996 , Marx 1998 .
Carcinoid tumours
Carcinoid tumours which occur more frequently in patients with MEN1 may be inherited as an autosomal dominant trait in association with MEN1 (Duh et al. 1987) . The carcinoid tumour may be located in the bronchi, the gastrointestinal tract, the pancreas, or the thymus. Most patients are asymptomatic and do not suffer from the flushing attacks and dyspnoea associated with the carcinoid syndrome, which usually develops after the tumour has metastasised to the liver.
Adrenal corticol tumours
The incidence of asymptomatic adrenal cortical tumours in MEN1 patients has been reported to be as high as 40% (Skogseid et al. 1992) . The majority of these tumours are non-functioning. However, functioning adrenal cortical tumours in MEN1 patients have been documented to cause hypercortisolaemia and Cushing's syndrome, and primary hyperaldosteronism, as in Conn's syndrome (Thakker 1995 , Trump et al. 1996 .
Lipomas
Lipomas may occur in 20%-30% of patients (Darling et al. 1997 , Marx 1998 , and frequently they are multiple. In addition, pleural or retroperitoneal lipomas may also occur in patients with MEN1.
Thyroid tumours
Thyroid tumours, consisting of adenomas, colloid goitres and carcinomas have been reported to occur in over 25% of MEN1 patients (Thakker 1995 , Marx 1998 ). However, the prevalence of thyroid disorders in the general population is high and it has been suggested that the association of thyroid abnormalities in MEN1 patients may be incidental and not significant.
Facial angiofibromas and collagenomas
Multiple facial angiofibromas, which are identical to those observed in patients with tuberous sclerosis, have been observed in 88% of MEN1 patients (Darling et al. 1997 , Marx 1998 , and collagenomas have been reported in > 70% of MEN1 patients (Darling et al. 1997 , Marx 1998 ).
Molecular genetics of MEN1

Models of tumour development
The development of tumours may be associated with mutations or inappropriate expression of specific normal cellular genes, which are referred to as oncogenes (reviewed in Thakker & Ponder 1988 , Thakker 1993 , 1994 1995 , Brown & Solomon 1997 . Two types of oncogenes, referred to as dominant and recessive oncogenes, have been described. An activation of dominant oncogenes leads to transformation of the cells containing them, and examples of this are the chromosomal translocations associated with the occurrence of chronic myeloid leukaemia and Burkitt's lymphoma. In these conditions, the mutations which lead to activation of the oncogene are dominant at the cellular level, and therefore only one copy of the mutated gene is required for the phenotypic effect. Such dominantly acting oncogenes may be assayed in cell culture by first transferring them into recipient cells and then scoring the numbers of transformed colonies, and this is referred to as the transfection assay. However, in some inherited neoplasms which may also arise sporadically, such as retinoblastoma, tumour development is associated with two recessive mutations which inactivate oncogenes, and these are referred to as recessive oncogenes. In the inherited tumours, the first of the two recessive mutations is inherited via the germ cell line and is present in all the cells. This recessive mutation is not expressed until a second mutation, within a somatic cell, causes loss of the normal dominant allele. The mutations causing the inherited and sporadic tumours are similar but the cell types in which they occur are different. In the inherited tumours the first mutation occurs in the germ cell, whereas in the sporadic tumours both mutations occur in the somatic cell. Thus, the risk of tumour development in an individual who has not inherited the first germline mutation is much smaller, as both mutational events must coincide in the same somatic cell. In addition, the apparent paradox that the inherited cancer syndromes are due to recessive mutations but dominantly inherited at the level of the family is explained because, in individuals who have inherited the first recessive mutation, a loss of a single remaining wild type allele is almost certain to occur in at least one of the large number of cells in the target tissue. This cell will be detected because it forms a tumour, and almost all individuals who have inherited the germline mutation will express the disease, even though they inherited a single copy of the recessive gene. This model involving two (or more) mutations in the development of tumours is known as the 'two hit' or Knudson's hypothesis (Knudson 1971 (Knudson , 1993 . The normal function of these recessive oncogenes appears to be in regulating cell
Figure 1
Loss of heterozygosity (LOH) involving polymorphic loci from chromosome 11 in a parathyroid tumour from a patient with familial MEN1. The microsatellite polymorphisms obtained from the patient's leucocyte (L) and parathyroid tumour (T) DNA at the PTH, D11S480, phosphorylase glycogen muscle (PYGM), D11S970 and apolipoprotein C-III (APOCIII) loci are shown. These microsatellite polymorphisms have been identified using specific primers for each of the loci which have been localised to chromosome 11, and are shown juxtaposed to their region of origin on the short (p) and long (q) arms of chromosome 11. The microsatellite polymorphisms are assigned alleles (see Fig. 2 ). For example D11S480 yielded a 197 bp product (allele 1) and a 189 bp product (allele 2) following PCR amplification of leucocyte DNA, but the tumour cells have lost the 197 bp product (allele 1) and are hemizygous (alleles -,2). Similar losses of alleles are detected using the other DNA markers, and an extensive loss of alleles involving the whole of chromosome 11 is observed in the parathyroid tumour of this patient with MEN1. In addition, the complete absence of bands suggests that this abnormality has occurred within all the tumour cells studied, and indicates a monoclonal origin for this MEN1 parathyroid tumour. (From Pang & Thakker (1994) , with permission.) growth and differentiation, and these genes have also been referred to as anti-oncogenes or tumour suppressor genes. An important feature which has facilitated the investigation of these genetic abnormalities associated with tumour development is that the loss of the remaining allele (i.e. the 'second hit'), which occurs in the somatic cell and gives rise to the tumour, often involves a large scale loss of chromosomal material. This 'second hit' may be Figure 2 Segregation of D11S480, a polymorphic locus from chromosome 11q13, and MEN1 in a family. Genomic DNA from the family members (upper panel) was used with [γ-32 P]adenosine triphosphate (ATP) for PCR amplification of the polymorphic repetitive element (CA) n at this locus. The PCR amplification products were separated on a polyacrylamide gel and detected by autoradiography (lower panel); these ranged in size from 189 to 199 bp. Alleles were designated for each PCR product and are indicated on the right. For example, individuals II.1, II.2 and III.1 reveal 2 pairs of bands on autoradiography. The upper pair of bands is designated allele 1 and the lower pair of bands is designated allele 3; and these 3 individuals are therefore heterozygous (alleles 1, 3). A pair of bands for each allele is frequently observed in the PCR detection of microsatellite repeats. The upper band in the pair is the 'true' allele and the lower band in the pair is its associated 'shadow' which results from slipped-strand mispairing during the PCR. The segregation of these bands and their respective alleles together with the disease can be studied in the family members whose alleles and ages are shown. In some individuals, the inheritance of paternal and maternal alleles can be ascertained; the paternal allele is shown on the left. Individuals are represented as unaffected male (open square), affected male (filled square), unaffected female (open circle), and affected female (filled circle). Individual II.2 is affected and heterozygous (alleles 3, 1) and an examination of her affected child (III.1), grandchild (IV.2), sibling (II.5) and niece (III.4) reveals inheritance of allele 3 with the disease. The unaffected individuals II.3, II.4, and III.3 have not inherited this allele 3. However, the daughter (IV.1) of individual III.1 has inherited allele 3, but remains unaffected at the age of 20 years; this may either be a representation of age-related penetrance (see Fig. 5 ), or a recombination between the disease and D11S480 loci. Thus, in this family, the disease and D11S480 loci are co-segregating in 8 out of the 9 children, but in one individual (IV.1), assuming a 100% penetrance (see below) in early childhood, recombination is observed. Thus, MEN1 and D11S480 are co-segregating in 8/9 of the meioses and not segregating in 1/9 meioses, and the likelihood that the two loci are linked at θ=0.11, i.e. 11% recombination, is (8/ 9) 8 × (1/9) 1 . If the disease and the D11S480 loci were not linked, then the disease would be associated with allele 1 in one half (1/2) of the children and with allele 3 in the remaining half (1/2) of the children, and the likelihood that the two loci are not linked is (1/2) 9 . Thus, the odds ratio in favour of linkage between the MEN1 and D11S480 loci at θ=0.11, i.e. 11% in this family, is therefore (8/9) 8 × (1/9) 1 ÷(1/2) 9 =22.17:1, and the LOD score (i.e. log 10 of the odds ratio favouring linkage)=1.34 (i.e. log 10 22.17). A LOD score of +3 which indicates a probability in favour of linkage of 1000:1 establishes linkage. LOD scores from individual families can also be summated, and such studies revealed that the peak LOD score between MEN1 and the DS11S480 locus was >+3 , thereby establishing linkage between MEN1 and D11S480 loci.
detected by a comparison of the DNA sequence polymorphisms in the leucocytes and tumour obtained from a patient, and observing a loss of heterozygosity (LOH) in the tumour (Fig. 1) .
Identification of the MEN1 gene
The gene causing MEN1 was localised to chromosome 11q13 by genetic mapping studies which investigated MEN1-associated tumours for LOH ( Fig. 1 ) and by segregation studies in MEN1 families (Fig. 2) (Larsson et al. 1988 , Friedman et al. 1989 , Thakker et al. 1989 , Byström et al. 1990 ). The results of these studies, which were consistent with Knudson's model for tumour development, indicated that the MEN1 gene represented a putative tumour suppressor gene. Further genetic mapping studies defined a < 300 kb region as the minimal critical segment that contained the MEN1 gene and characterisation of genes from this region led to the identification, in 1997, of the MEN1 gene (The European Consortium on MEN1 1996 , which consists of 10 exons with a 1830 bp coding region ( Fig. 3 ) that encodes a novel 610 amino acid protein, referred to as MENIN . Mutations of the MEN1 gene (Figs 3 and 4) have been identified and the total number of germline mutations of the MEN1 gene that have been identified by 21 studies , Debelenko et al. 1997b , Mayr et al. 1997 , Shimizu et al. 1997 , Toliat et al. 1997 , Bartsch et al. 1998 , Bassett et al. 1998 , Chico et al. 1998 , Giraud et al. 1998 , Kishi et al. 1998 , Sato et al. 1998 , Tanaka et al. 1998 , Teh et al. 1998a ,b,c, Gortz et al. 1999 , Poncin et al. 1999 during the past 2 years in MEN1 patients is 262 (Table 2) . . The 1.83 kb coding region is organised into 9 exons (exons 2 to 10) and 8 introns (indicated by a line but not to scale). The sizes of the exons (boxes) range from 88 to 1312 bp and those of the introns range from 41 to 1564 bp. The start (ATG) and stop (TGA) sites in exons 2 and 10, respectively, are indicated. Exon 1, the 5' part of exon 2 and 3' part of exon 10 are untranslated (indicated by the hatched boxes). The locations of the two nuclear localisation sites (NLS), which are at codons 479 to 497, and 588 to 608 at the C-terminus, are represented by the thick horizontal lines, and the locations of the 3 domains, which are formed by codons 1 to 40 (exon 2), 139 to 242 (exons 2, 3 and 4) and 323 to 428 (exons 7, 8 and 9), that interact with JunD are indicated by the stippled boxes. The sites of the 262 germline mutations (panel A) and 67 somatic mutations (panel B) are indicated by the vertical lines; the missense and in-frame mutations are represented above the gene and the nonsense, frameshift and splice site mutations are represented below the gene. The detailed descriptions of these 329 mutations are given in Table 2 . Mutations which have occurred more than 4 times (scale shown on the right) are indicated. The deletion has caused a frameshift which continues to codon 223 before a stop codon (TGA) is encountered in the new frame. The 1 bp deletion results in the loss of an MspI restriction enzyme site (C/CGG) from the normal (wild type, WT) sequence (panel a) and this has facilitated the detection of this mutation in the other affected members (II.4, III.3, and III.4) of this family (panel b). The mutant (m) PCR product is 190 bp whereas the wild type (WT) products are 117 and 73 bp (panel c). The affected individuals were heterozygous, and the unaffected members were homozygous for the wild type sequence. Individuals III.6 and III.10, who are 40 and 28 years old respectively, are mutant gene carriers who are clinically and biochemically normal and this is due to the age-related penetrance of this disorder (see Fig. 5 ). Individuals are represented as: male (square); female (circle); unaffected (open); affected with parathyroid tumours (filled upper right quadrant), with gastrinoma (filled lower right quadrant), with prolactinoma (filled upper left quadrant); and unaffected mutant gene carriers (dot in the middle of the open symbol). Individual I.2 who is deceased but was known to be affected (tumour details not known) is shown as a filled symbol. The age is indicated below for each individual at diagnosis or at the time of the last biochemical screening. The standard size marker (S) in the form of the 1 kb ladder is indicated. Co-segregation of this mutation with MEN1 in family 8/89 and its absence in 110 alleles from 55 unrelated normal individuals (N 1-3 shown) indicates that it is not a common DNA sequence polymorphism. (Adapted from Bassett et al. (1998) , with permission.) 220bp 134bp m WT Approximately 22% are nonsense mutations, ≈48% are frameshift deletions or insertions, 8% are in-frame deletions or insertions, 5% are donor-splice site mutations and ≈17% are missense mutations. More than 10% of the MEN1 mutations arise de novo and may be transmitted to subsequent generations , Bassett et al. 1998 , Teh et al. 1998a . It is also important to note that between 5% to 10% of MEN1 patients may not harbour mutations in the coding region of the MEN1 gene , The European Consortium on MEN1 1997 , Bassett et al. 1998 , Giraud et al. 1998 , Teh et al. 1998a , and that these individuals may have mutations in the promoter or untranslated regions (UTRs), which remain to be investigated.
The majority (75%) of the MEN1 mutations are inactivating, and are consistent with those expected in a tumour suppressor gene. The mutations are not only diverse in their types but are also scattered (Fig. 3 ) throughout the 1830 bp coding region of the MEN1 gene with no evidence for clustering as observed in MEN2 (Table 1) (Gagel & Cotes 1996) . However, some of the mutations have been observed to occur several times in unrelated families (Table 2 and Fig. 3) , and the 4 deletional and insertional mutations involving codons 83 and 84, codon 119, codons 209 to 211, and codons 514 to 516, account for approximately 19% of all the germline MEN1 mutations, and thus these may represent potential 'hot' spots. Such deletional and insertional hot spots may be associated with DNA sequence repeats that may consist of long tracts of either single nucleotides or shorter elements, ranging from dinucleotides to octanucleotides. Indeed, the DNA sequence in the vicinity of codons 83 and 84 in exon 2, and codons 209 to 211 in exon 3, contains CT and CA dinucleotide repeats, respectively, flanking the 4 bp deletions (Table 2) ; these would be consistent with a replication-slippage model in which there is misalignment of the dinucleotide repeat during replica-tion, followed by excision of the 4 bp single-stranded loop (Bassett et al. 1998) . A similar replication-slippage model may also be involved at codons 119 to 120 which both consist of AAG nucleotides encoding a lysine (K) residue ( Table 2) . The deletions and insertions of codon 516 involve a poly(C)7 tract, and a slipped-strand mispairing model is also the most likely mechanism to be associated with this mutational hot spot (Bassett et al. 1998 ). Thus, the MEN1 gene appears to contain DNA sequences that may render it susceptible to deletional and insertional mutations.
Correlations between the MEN1 mutations and the clinical manifestations of the disorder appear to be absent. For example, a detailed study of 5 unrelated families with the same 4 bp deletion in codons 210 and 211 (Table 3) revealed a wide range of MEN1-associated tumours (Bassett et al. 1998 ); all the affected family members had parathyroid tumours, but members of families 1, 3, 4 and 5 had gastrinomas whereas members of family 2 had insulinomas. In addition, prolactinomas occurred in members of families 2, 3, 4 and 5 but not members of family 1, which were affected with carcinoid tumours. The apparent lack of genotype-phenotype correlations, which contrasts with the situation in MEN2 (Table 1) (Gagel & Cotes 1996) , together with the wide diversity of mutations in the 1830 bp coding region of the MEN1 gene, will make mutational analysis for diagnostic purposes in MEN1 time-consuming and expensive (Thakker 1998) .
MEN1 mutations in sporadic non-MEN1 endocrine tumours
Parathyroid, pancreatic islet cell, and anterior pituitary tumours may occur either as part of MEN1 or, more commonly, as sporadic, non-familial, tumours. Tumours from MEN1 patients have been observed to harbour the germline mutation together with a somatic LOH involving chromosome 11q13 (Larsson et al. 1988 , Friedman et al. 1989 , Thakker et al. 1989 , Byström et al. 1990 ), as expected from Knudson's model and the proposed role of the MEN1 gene as a tumour suppressor. However, LOH involving chromosome 11q13, which is the location of the MEN1, has also been observed in 5% to 50% of sporadic endocrine tumours, implicating the MEN1 gene in the aetiology of these tumours (Byström et al. 1990 . Somatic MEN1 mutations ( Fig. 3 and Table 2 ) have been detected in 13% of sporadic parathyroid tumours (total number, n=150) , Farnebo et al. 1998 , Shan et al. 1998 ), 39% of gastrinomas (n=54) , Wang et al. 1998 , Mailman et al. 1999 ), 17% of insulinomas (n=18) , Shan et al. 1998 ), 66% of VIPomas (n=3) (Shan et al. 1998 , Wang et al. 1998 ), 13% of non-functioning pancreatic tumours (n=15) ), 100% of glucagonomas (n=2) ), 1.5% of adrenal cortical tumours (n=68) (Gortz et al. 1999 ), 36% of bronchial carcinoid tumours (n=11) (Debelenko et al. 1997b ), 40% of anterior pituitary adenomas (n=117) (Zhuang et al. 1997b , Prezant et al. 1998 , Tanaka et al. 1998 , 10.5% of angiofibromas (n=19) (Boni et al. 1998 ) and 17% of lipomas (n=6) ). These 67 somatic mutations are scattered through the 1830 bp coding region (Fig. 3) , and 9% are nonsense mutations, 45% are frameshift deletions or insertions, 6% are in-frame deletions or insertions, 4% are donor-splice site mutations, and 36% are missense mutations (Table 2) . A comparison of the locations of the somatic and germline mutations revealed a higher frequency (43% (somatic) versus 27% (germline), P<0.001) of somatic mutations in exon 2, and the significance of this observation (Pannett & Thakker (Debelenko et al. 1997b , Toliat et al. 1997 ,b, Boni et al. 1998 , Farnebo et al. 1998 , Prezant et al. 1998 , Shan et al. 1998 , Wang et al. 1998 , Gortz et al. 1999 , Mailman et al. 1999 indicate that although inactivation of the MEN1 gene may have a role in the aetiology of some sporadic endocrine tumours, the involvement of other genes with major roles in the aetiology of such sporadic endocrine tumours is highly likely.
Function of MEN1 protein (MENIN)
Initial analysis of the predicted amino acid sequence encoded by the MEN1 gene did not reveal homologies to any other proteins, sequence motifs, signal peptides, or consensus nuclear localisation signals , and thus the putative function of the protein (MENIN) could not be deduced. However, studies based on immunofluorescence, Western blotting of subcellular fractions, and epitope tagging with enhanced green fluorescent protein, revealed that MENIN was located primarily in the nucleus (Guru et al. 1998 ). Furthermore, enhanced green fluorescent protein-tagged MENIN deletional constructs identified at least two independent nuclear localisation signals that are located in the C-terminal quarter of the protein (Fig. 3) (Guru et al. 1998) . Interestingly, none of the MEN1 germline missense or in-frame deletions , Debelenko et al. 1997b , Mayr et al. 1997 , Shimizu et al. 1997 , Toliat et al. 1997 , Zhuang et al.1997a , Bartsch et al. 1998 Bassett et al. 1998 , Chico et al. 1998 , Giraud et al. 1998 , Kishi et al. 1998 , Sato et al. 1998 , Tanaka et al. 1998 , Teh et al. 1998a ,b,c, Gortz et al. 1999 , Poncin et al. 1999 ) alter either of these putative nuclear localisation signals (Fig. 3) . However, all of the truncated MEN1 proteins that would result from the nonsense and frameshift mutations, if expressed, would lack at least one of these nuclear localisation signals (Fig. 3) . The nuclear localisation of MENIN suggested that it may act either in the regulation of transcription, or DNA replication, or the cell cycle. In order to investigate this further and to identify proteins that may interact with MENIN, the yeast two hybrid system was utilised. This revealed that MENIN directly interacts with the Nterminus of the AP-1 transcriptional factor JunD, to repress JunD-activated transcription (Agarwal et al. 1999) . Analysis of several MEN1 missense and deletional mutations indicated that the N-terminus and central domains of MENIN (Fig. 3 ) have a critical role in MENIN-JunD interaction. However, JunD inhibits cell growth (Hirai et al. 1989 , Ryder et al. 1989 , Pfarr et al. 1994 , an action that differs from that of other AP-1 proteins, and thus the repressive effect of MENIN on JunD-mediated transcriptional activation would predict enhanced growth rather than the observed suppression in growth. This seeming paradox may be due to the involvement of other target genes and proteins that may be involved in cell proliferation and that may have interactions with the MENIN-JunD complex (Agarwal et al. 1999 ). These suggestions are further supported by the observation that disease-associated mutations which occur outside the domains interacting with JunD (Fig. 3) , are associated with normal MENIN-JunD binding; this suggests that MENIN may interact with other proteins that may influence JunD-mediated transcription. Further investigations are needed to elucidate the role of MENIN-JunD interactions in the control of endocrine cell proliferation.
Screening in MEN1
MEN1 is inherited as an autosomal dominant disorder in the majority of patients. Occasionally, MEN1 may arise sporadically (i.e. without family history), although it may be difficult to make the distinction between sporadic and familial forms; in some cases the family history may be The age distributions (panel A) and age-related penetrances (panel B) of MEN1 determined from an analysis of 174 mutant gene carriers. The age distributions were determined for 3 groups of MEN1 mutant gene carriers from 40 families in whom mutations were detected (Bassett et al. 1998) . The 91 members of group A presented with symptoms, whereas the 40 members of group B were asymptomatic and were detected by biochemical screening. The 43 members of group C represent those individuals who are MEN1 mutant gene carriers ( Fig. 4) and who remain asymptomatic and biochemically normal. The ages included for members of groups A, B and C are those at the onset of symptoms, at the finding of the biochemical abnormality, and at the last clinical and biochemical evaluation respectively. Groups B and C contained members who were significantly younger than those in group A (P<0.001). The younger age of the group C mutant gene carriers is consistent with an age-related penetrance for MEN1, and this was calculated (panel B) for the first 5 decades. The age-related penetrances (i.e. the proportion of mutant gene carriers with manifestations of the disease by a given age) rose steadily from 7% in the <10 years group, to 52%, 87%, 98% and 100%, by the ages of 20, 30, 40, and 60 years respectively. (Adapted from Bassett et al. (1998) , with permission.) absent because the parent with MEN1 is not available, and has perhaps already died before developing any manifestations, and other cases may be due to de novo mutations, which will be transmitted in an autosomal dominant manner in future generations , Bassett et al. 1998 , Teh et al. 1998a . MEN1 is an uncommon disorder, but because of its autosomal dominant inheritance, the finding of MEN1 in a patient has important implications for other family members; firstdegree relatives have about a 50% risk of developing the disease. Screening for MEN1 in patients involves the detection of tumours and the ascertainment of the germline genetic state i.e. normal or mutant gene carrier. The detection of tumours entails clinical, biochemical and radiological investigations for MEN1-associated tumours in patients. The recent cloning of the MEN1 gene has facilitated the identification of individuals who have mutations and hence are at a high risk of developing the disease (Figs 3 and 4 ).
Genetic analysis
Mutational analysis for MEN1 could now be introduced to identify those individuals who are mutant carriers and thus at a high risk of developing tumours. The advantages of DNA analysis are that it requires a single blood sample and does not need, in theory, to be repeated. This is because the analysis is independent of the age of the individual and provides an objective result. Such mutational analysis could be undertaken in children around the first decade, as some children have developed tumours by the age of 8 years (Thakker 1995 , Trump et al. 1996 , and appropriate intervention in the form of biochemical testing and/or treatment has been considered. However, the great diversity together with the widely scattered locations of the MEN1 mutations (Fig. 3) , and a lack of genotype-phenotype correlation (Table 3 ) will make such mutational screening time-consuming, arduous and expensive, and as yet this is not widely available. Nevertheless, an integrated programme of both mutational analysis, to identify mutant gene carriers, and biochemical screening, to detect the development of tumours, would be of advantage. Thus, a DNA test identifying an individual as a mutant gene carrier is likely to lead not to immediate medical or surgical treatment but to earlier and more frequent biochemical and radiological screening, whereas a DNA result that indicates that an individual is not at risk will lead to a decision for no further clinical investigations. Thus, the identification of MEN1 mutations may be of help in the clinical management of patients and their families with this disorder.
Detection of MEN1 tumours
Biochemical screening for the development of MEN1 tumours in asymptomatic members of families with MEN1 is of great importance, as earlier diagnosis and treatment of these tumours may help to reduce morbidity and mortality. The age-related penetrance (i.e. the proportion of gene carriers manifesting symptoms or signs of the disease by a given age) has been ascertained ( Fig. 5 ) and the mutation appears to be non-penetrant below the age of 8 years. Thereafter, the mutant MEN1 gene has a high penetrance, being >50% penetrant by 20 years of age and >95% penetrant by 40 years (Bassett et al. 1998) . Screening for MEN1 tumours is difficult because the clinical and biochemical manifestations in members of any one family are not uniformly similar (Trump et al. 1996) . The attempts to screen for the development of MEN1 tumours in the asymptomatic relatives of an affected individual have depended largely on measuring the serum concentrations of calcium, gastrointestinal hormones and prolactin, and also on ultrasound and radiological imaging of the abdomen and pituitary. Parathyroid overactivity causing hypercalcaemia is almost invariably the first manifestation of the disorder and this has become a useful and easy biochemical screening investigation (Benson et al. 1987 , Marx et al. 1986 . At present, it is suggested that individuals at high risk of expressing MEN1 (i.e. mutant gene carriers) should undergo biochemical screening at least once per annum, and also have baseline pituitary and abdominal imaging, which should then be repeated infrequently (at 5 to 10 yearly intervals). Screening should commence in early childhood, as the disease has developed in some individuals by the age of 8 years, and should continue for life, as some individuals have not developed the disease until the eighth decade. Screening history and physical examination should be directed towards eliciting the symptoms and signs of hypercalcaemia, nephrolithiasis, peptic ulcer disease, neuroglycopaenia, hypopituitarism, galactorrhoea and amenorrhoea in women, acromegaly, Cushing's disease, visual field loss and the presence of subcutaneous lipomata, angiofibromas, and collagenomas. Biochemical screening should include serum calcium and prolactin estimations in all individuals, and measurement of gastrointestinal hormones e.g. gastrin, and more specific endocrine function tests should be reserved for individuals who have symptoms or signs suggestive of a clinical syndrome.
